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Abstract
Achieving adequate but not excessive sedation in critically ill,
mechanically ventilated patients is a complex process. Analgesics
and sedatives employed in this context are extremely potent, and
drug requirements and metabolism are unpredictable. Clinicians
must have heightened awareness of the potential for enduring
effects and are encouraged to employ strategies that maximize
benefit while minimizing risk. Successful sedation protocols have
three basic components: frequent assessments for pain, anxiety,
and agitation using a reproducible scale; combination therapy
coupling opioids and sedatives; and, most importantly, careful
communication between team members, with a particular
recognition that the bedside nurse must be empowered to pair
assessments with drug manipulation. In recent years, two broad
categories of sedation protocols have achieved clinical success in
terms of decreasing duration of mechanical ventilation and
intensive care unit length of stay by minimizing drug accumulation.
Patient-targeted sedation protocols (the first category) rely on
structured assessments to guide a careful schema of titrated drug
escalation and withdrawal. Variation exists in the assessment tool
utilized, but the optimal goal in all strategies is a patient who is
awake and can be readily examined. Alternatively, daily interruption
of continuous sedative infusions (the second category) may be
employed to focus care providers on the goal of achieving a period
of awakening in the earliest phases of critical illness possible.
Newer literature has focused on the safety of this strategy and its
comparison with intermittent drug administration. Ongoing
investigations are evaluating the broad applicability of these types
of protocols, and currently one may only speculate on whether one
strategy is superior to another.
Introduction
Ensuring patient comfort and safety is a universal goal for
critical care practitioners. Patients undergoing mechanical
ventilation experience significant stress superimposed on
their acute medical problem, ranging from anxiety about their
surroundings and condition to distress with potential pain
from necessary nursing care and procedures. Non-
pharmacologic therapies such as comfortable positioning in
bed and verbal reassurance are reasonable initial considera-
tions, but a need for sedatives and analgesics to promote
tolerance to the intensive care unit (ICU) environment is
typically the rule.
Sedation needs vary widely in mechanically ventilated patients.
ICU patients frequently exhibit unpredictable pharmacology
with accumulation of drug in tissue stores, resulting in a
prolonged clinical effect. Other variables that confound
attempts to predict drug effect include renal and hepatic
dysfunction, drug-drug interactions, hypoproteinemia, and
shock. As a result, sedatives and analgesics must be titrated
to discernible and reproducible clinical end-points. Because
the drugs used in this context are extremely potent, clinicians
must have heightened awareness of the potential for
enduring effects and are encouraged to employ strategies
that maximize benefit while minimizing risk.
The risk for untreated pain or agitation is a primary concern.
Most mechanically ventilated patients experience some
degree of pain even in the absence of surgical incisions or
trauma [1,2]. Accordingly, it is critical for clinicians to direct
initial attention toward analgesia when they administer
‘sedation’. Untreated pain may cause many adverse effects,
including increased endogenous catecholamine activity,
myocardial ischemia, hypercoagulability, hypermetabolic
states, sleep deprivation, anxiety, and delirium [3]; treating
this pain has been shown to ameliorate some of these effects
[4]. Untreated agitation, particularly in the delirious patient,
may result in similar problems, including patient self-injury via
removal of life-sustaining devices.
In contrast, some patients may exhibit extreme hypertension,
tachycardia, tachypnea, and ventilator asynchrony even in a
comatose state. These findings are particularly common in
unconventional ventilation strategies (low tidal volumes, per-
missive hypercapnea, high-frequency oscillatory ventilation,
and prone positioning) and may counter the body’s usual
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response to stress. With increasing acuity of illness, it may
become difficult to reconcile the goals of ensuring patient
tranquility while preventing accumulation of sedatives and
analgesics.
The resulting deep sedation may have significant unintended
consequences. Kollef and coworkers [5] studied the out-
comes of 240 mechanically ventilated patients stratified by
sedation strategy, namely continuous intravenous sedation or
interrupted/no intravenous sedation. Patients undergoing
continuous intravenous sedation had markedly increased
duration of mechanical ventilation, ICU and hospital length of
stay, organ system failure, and re-intubation rates (Figure 1).
Although the study is limited by the lack of randomization, the
difference in duration of mechanical ventilation persisted after
multivariate analysis incorporating severity of illness, mortality,
indication for mechanical ventilation, use of chemical
paralysis, presence of tracheostomy, and number of acquired
organ system derangements.
Additionally, investigators are now measuring other deleterious
outcomes that may (at least in part) stem from sedation.
Central nervous system dysfunction, manifested as delirium,
occurs in 60% to 80% of patients undergoing mechanical
ventilation [6-8]. ICU delirium is predictive of a threefold
higher re-intubation rate and more than 10 additional days in
the hospital, and it is independently associated with higher
ICU, inpatient, and 6-month mortality rates [9-12]. An
evaluation of sedative and analgesic use in ICU patients [13]
demonstrated a dose-related association between lorazepam
administration and the daily transition to delirium. Studies are
now ongoing to identify a cause-effect relationship in order to
evaluate whether serial assessments for delirium will promote
improved sedation behaviors and patient outcomes.
The ideal sedative and analgesic regimen will provide
adequate sedation and pain control, be of rapid onset of
action and allow rapid recovery after discontinuation, have
minimal systemic accumulation, and carry minimal adverse
effects, without increasing overall health care costs (which is
a challenge in the development of a novel drug or applica-
tion). Candidate drugs include ultra-short-acting agents such
as remifentanil and another class of agent (other than
propofol, benzodiazepines, and opioids) such as the α2
adrenergic agonist dexmedetomidine. These drugs (discussed
in detail in other reviews included in this supplement [14,15])
herald great promise in longer term analgesia and sedation
strategies. Further studies of these drugs’ influence on
outcomes such as duration of mechanical ventilation, length
of ICU stay, mortality, and delirium will help to establish their
role in routine practice.
Until that time, reliance upon short-acting (propofol) and inter-
mediate- and long-acting (benzodiazepines and opioids)
agents is common practice, and recent clinical trials now
permit an evidence-based approach to analgesia and seda-
tion management in the ICU. To understand how sedation
protocols should function optimally, we review the evidence
and practical implementation of researched strategies.
Patient-targeted sedation protocols
Patient-targeted sedation protocols implement two main
features: a structured approach to the assessment of patient
pain and distress, coupled with an algorithm that directs drug
escalation and de-escalation based on the assessments.
Limited data suggest that routine, structured assessments
alone may effect substantial change on outcomes. Chanques
and coworkers [16] studied the frequency of pain and
agitation in ICU patients in a period preceding and following
the incorporation of analgesia and sedation scales. In the
initial phase, no systematic and objective evaluation of pain or
agitation was performed by nurses or physicians. During a
brief interphase, nurses and physicians were educated on the
application of the Behavioral Pain Scale [17], Numerical
Rating Scale for pain [18], and the Richmond Agitation
Sedation Scale [19]. During the intervention phase, critically
ill patients experienced less pain and agitation (although
assessments were not conducted by independent
observers), more frequent titrations of both analgesic and
psychoactive drugs were performed, and duration of
mechanical ventilation was reduced.
More robust data exist documenting the success of protocols
that link assessments to consequent actions. Patient-targeted
sedation protocols have been tested in multiple investigations
conducted in the setting of single-center, two-phase,
prospective, controlled studies, with varying degrees of
Figure 1
Duration of mechanical ventilation: continuous intravenous sedation
versus interrupted/no intravenous sedation. Shown are Kaplan-Meier
curves for patients receiving continuous intravenous sedation (CIVS)
and patients not receiving continuous intravenous sedation. Reprinted
with permission from Chest 1998, 114:541-548. © American College
of Chest Physicians.
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success [20-23]. However, the most compelling data
supporting patient-targeted protocols comes from a
randomized, controlled clinical trial of 321 patients receiving
mechanical ventilation conducted in an urban teaching
hospital’s medical ICU (MICU). Brook and coworkers [24]
compared the practice of protocol-directed sedation during
mechanical ventilation implemented by nurses versus
traditional non-protocol-directed administration of sedation. In
patients randomly assigned to receive the protocol-directed
sedation, nurses determined whether sedatives or analgesics,
or both, were needed to provide optimal patient care. The
type of sedation administration (intravenous bolus adminis-
tration versus continuous intravenous infusion) and the
dosage were determined by nursing staff, targeting an ideal
level of sedation. In contrast, treating physicians managed all
aspects of sedation in the non-protocol-directed group. In
this latter group, nurses were able to communicate their
opinions and observations, but they could not make changes
without a physician’s order. Although protocol deviation was
allowed, the majority of patients were treated with benzo-
diazepines for sedation and fentanyl or morphine for analgesia.
The application of protocol-directed sedation resulted in a
significantly shorter duration of mechanical ventilation (median
duration 55.9 hours) compared with those receiving non-
protocol-directed sedation (117.0 hours) [24]. Additionally,
ICU and hospital lengths of stay were both significantly
shorter among patients in the protocol-directed sedation
group. Approximately 40% of patients in each group
underwent continuous intravenous sedation, but those in the
protocol-directed sedation group had a significantly shorter
duration of continuous infusion (3.5 days versus 5.6 days;
P = 0.003). Patients in the protocol-directed sedation group
also had a significantly lower tracheostomy rate than did
those in the non-protocol-directed sedation group.
In practice, this protocol emphasized the importance of an
initial assessment of analgesic needs followed by an assess-
ment for agitation. Utilizing a combination of benzodiazepine
and opioids, nurses sought to achieve an ideal level of
sedation, defined as a score of 3 on the Ramsay Sedation
Scale (patient responds to commands only) [25]. If frequent
administrations of extra boluses of sedative or opioid were
necessary, then continuous infusions were begun. Reassess-
ment occurred at least every 4 hours, and downward titration
of infusion rates was targeted until the infusion was stopped.
Most recently, De Jonghe and coworkjers [20] demonstrated
that similar success can be achieved with the implementation
of a sedation protocol that utilizes a more comprehensive
patient assessment tool. To date, the majority of sedation
protocols have relied upon the Ramsay Sedation Scale score,
but this scale has attracted criticism because of its lack of
clear discrimination and specific descriptors to differentiate
between the various levels [26,27]. Furthermore, attention to
agitation and ventilator synchrony is absent. In contrast, the
Adaptation to the Intensive Care Unit Environment (ATICE)
tool consists of five items (Figure 2) [28]: calmness, ventilator
Available online http://ccforum.com/content/12/S3/S6
Figure 2
ATICE instrument. ATICE, Adaptation to the Intensive Care Unit Environment. Adapted with permission from De Jonghe B, Cook D, Griffith L,
Appere-de-Vecchi C, Guyatt G, Theron V, Vagnerre A, Outin H: Adaptation to the Intensive Care Environment (ATICE): development and validation
of a new sedation assessment instrument. Crit Care Med 2003, 31(9):2344-2354.
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domain, and awakeness and comprehension combined in a
‘consciousness’ domain. Prior work had demonstrated that the
scale, developed by a multidisciplinary team of nurses and
physicians, exhibited high internal consistency, inter-rater
reliability across disciplines, and validity. This instrument
correlates well both with several published sedation scales and
with amounts of sedatives and analgesics given to patients.
In the study conducted by De Jonghe and coworkers [20],
the ATICE assessment was paired with a sedation algorithm
that initially evaluated patients’ ‘tolerance’ to the ICU environ-
ment (measuring calmness, ventilator synchrony, and facial
expression; Figure 3). Derangements in any one of the
categories prompted further sedative or opioid administration
(assuming verbal reassurance and ventilator manipulation
were ineffective). Patients with tolerance were then assessed
for ‘consciousness’, in which sedatives and opioids were
titrated down to achieve an interactive patient who could
reply to commands and queries regarding the presence of pain.
Outcomes in 102 mechanically ventilated patients without
acute brain injury were measured during two 6-month time
periods [20]: preceding and following the implementation of
the ATICE-based sedation protocol. Median duration of
mechanical ventilation was significantly shorter in the algorithm
group. This difference persisted with multivariate analysis that
included factors such as severity of illness and organ
dysfunction. Most importantly, the median time to arousal was
also significantly shorter in patients in the algorithm group
(2 days) than in the control group (4 days; P = 0.006). This
documented shortening of time to arousal is considered to be
the most potent mechanism whereby sedation protocols can
reduce the duration of mechanical ventilation.
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Figure 3
ATICE-based Sedation and Analgesia Algorithm. Adaptation to the Intensive Care Unit Environment (ATICE) is measured every 3 hours, except
during the night in patients with satisfactory consciousness at the end of the day. ATICE is measured more frequently in patients with worsening
tolerance. The algorithm is not applied while patients are receiving neuromuscular blockers, in the prone position, or after an end-of-life decision
has been made. *Stricter objectives of tolerance (calmness = 3, ventilator synchrony = 4) may transiently be used in patients with severe acute
respiratory or circulatory failure. †During the initial 48-hour postoperative period, do not decrease fentanyl under 50 to 100 μg/hour. ↓, decrease
drug dosage; IV, intravenous; VAS, visual-analog scale. Reprinted with permission from De Jonghe B, Bastuji-Garin S, Fangio P, Lacherade JC,
Jabot J, Appere-De-Vecchi C, Rocha N, Outin H: Sedation algorithm in critically ill patients without acute brain injury. Crit Care Med 2005,
33(1):120-127.
Measurement of ATICE every 3 hours
YES NO
Next assessment
3 hours later
Next assessment
5 to 10 min later Measurement of ATICE
Is Tolerance satisfactory?
Ventilator                  Face
Calmness    and   Synchrony    and   Relaxation
2-3*                      3-4*                        2-3
Is Conciousness satisfactory?
Awakeness    and   Comprehension
4-5                            4-5
- search for cause of altered conciousness
not related to sedatives or analgesics
- decrease MIDAZOLAM (M) + FENTANYL (F):
M by 0.5 mg/hour every 3 hours 
F by 25 g/hour every 3 hours 
†
- search for a cause requiring sepcific treatment
- reassure the patient verbally and with gestures
- consider adapting ventilator to patient if Ventilator synchrony = 1 or 2
- consider IV analgesic bolus before nursing care if Face relaxation = 1
- start or increase MIDAZOLAM (M) + FENTANYL (F):
M/F 2 mg/100 g or 4 mg/200 g
according to level of poor tolerance
If no continuous infusion, start at hourly
dosage equal to bolus dose
If ongoing continuous infusion, increase
previous hourly dosage by bolus dose

Are you
in pain?
Maintain
current
dosage
Use
pain
VAS
to adapt
fentanyl
dosage
IV
continuous
IV bolus
YES
YES
NO
NOAnalgesic and sedative administration (irrespective of route
and type) guided to ensure patient safety and designed to
promote tolerance to an uncomfortable environment and
altered state of health can result in improved outcomes.
Seemingly, this result stems from a more rapid return to an
awake state, but other factors may be at play, including
avoidance of protracted immobility, ileus, delirium, and
dangerous agitation. Studies to explore these mechanisms
may help to guide the next generation of drug selection and
administration strategies.
Daily interruption of sedative infusions
If the primary goal is to achieve the earliest awakening
possible, then an alternative sedation protocol strategy that
may be applied is daily interruption of sedative infusions
(DIS). This strategy employs a similar goal of sedative and
analgesic titration to an optimal depth of sedation dictated by
physicians or nursing staff, or both. In contrast to ‘patient-
targeted sedation protocols’, no formal algorithm has been
established for drug escalation. However, the risk for
excessive sedation is minimized by a daily interruption of both
sedative and analgesic infusions until the patient awakens or
exhibits distress that mandates resumed drug administration.
This strategy was first introduced via a randomized controlled
trial involving 128 adult patients who were receiving mecha-
nical ventilation and continuous infusions of sedative drugs in
an academic MICU [29]. The study, designed in a factorial
2 × 2 design, randomly assigned patients by sedation
strategy: an intervention group, in which sedative infusions
were interrupted on a daily basis until the patients were
awake; and a control group, in which the infusions were
interrupted only at the discretion of the clinicians in the ICU.
The secondary randomization was based upon the sedative
employed, namely propofol or midazolam (treatment in both
groups was coupled with morphine for analgesia).
When the patients were evaluated by sedation strategy, the
median duration of mechanical ventilation was 4.9 days in the
intervention group versus 7.3 days in the control group
(P = 0.004), and the median lengths of stay in the ICU were
6.4 days and 9.9 days, respectively (P = 0.02; Figure 4) [29].
The DIS approach conferred additional advantages, including
a marked difference in the number of days during which
patients were awake and following commands (85.5% versus
9.0%; P < 0.001). This culminated in a significant reduction
in the need for diagnostic testing (via imaging or lumbar
puncture) to assess changes in mental status (9% of patients
versus 27%; P = 0.02). Complications related to under-
sedation (for instance, removal of the endotracheal tube by
the patient) were no different between groups (4% in the
intervention group versus 7% in the control group; P = 0.88).
Evaluation of groups based on sedative employed demon-
strated no difference between propofol and midazolam with
respect to the study’s primary end-points: duration of
mechanical ventilation, and ICU and hospital lengths of stay.
Of note, both total dosage and average rate of infusion for
both midazolam and morphine were reduced by half in the
intervention group (DIS). This reflects the ability of the DIS
approach to minimize drug accumulation and avoid delayed
drug emergence and so shorten the duration of mechanical
ventilation (akin to patient-targeted sedation protocols).
However, the protocol was equally effective for patients
randomly assigned to propofol infusion, prompting further
questions about possible unrecognized benefits that accrue
from complete interruption (reduced need for vasoactive
drug, less fluid administration, and spontaneous muscle
movement). Although the mechanism of benefit has not been
fully evaluated, the improved outcomes are compelling.
The practice of DIS generates more complex discussion than
patient-titrated sedation protocols. Both sedative and
analgesic agents should be interrupted once daily, unless
there is evidence for ongoing patient distress, reasonable
certainty that there is ongoing pain, or utilization of neuro-
muscular blockade. Once the drugs are interrupted, the ICU
team must be vigilant for evidence of patient distress, which
may manifest as overt physical agitation, isolated hemo-
dynamic  lability (hypertension or tachycardia), or ventilator
asynchrony. Providers are then encouraged to administer bolus
drug dosing to de-escalate symptoms, and restart both sedative
and analgesic drugs at half the previous infusion doses with
subsequent titration to the desired depth of sedation.
The study met with criticism because of its single center
application, absence of a standardized approach to ventilator
weaning, and, most markedly, concerns for potentially
unrecognized patient harm from the daily interruption [30].
These concerns include fear of precipitating psychologic
distress, myocardial ischemia, or drug and alcohol withdrawal
syndromes.
Long-term consequences of recovery from respiratory failure
include depression, anxiety, and post-traumatic stress
disorder (PTSD). Limited data suggest a positive relationship
between duration of sedation and development of depression
and PTSD [31]. Although it had traditionally been viewed that
unpleasant memories of critical illness may elicit psychiatric
illness, newer data suggest that the lack of recall of factual
events in the ICU is associated with a heightened risk for
PTSD in survivors [32]. Therefore, DIS creates a conundrum;
it may potentially be protective as a means to achieve
awakening with an increased likelihood of patient recall, or it
may risk further psychologic distress resulting from the nature
of the abrupt changes in level of consciousness.
To address this uncertain outcome, a cohort of survivors of
critical illness requiring mechanical ventilation and sedation
underwent psychologic assessment with outcomes stratified
by the sedation strategy [33]. Psychologists blinded to
patient randomization assessed for signs of PTSD, anxiety,
Available online http://ccforum.com/content/12/S3/S6
Page 5 of 10
(page number not for citation purposes)depression, and psychosocial adjustment to illness. The
cohort of patients who experienced DIS (versus continuous
sedative infusion) had a better total Impact of Events score
[34] (representing less frequent PTSD signs; 11.2 versus
27.3; P = 0.02), a trend toward a lower incidence of PTSD
[35] (0% versus 32%; P = 0.06), and a trend toward a better
total Psychosocial Adjustment to Illness score [36] (46.8
versus 54.3; P = 0.08). Patients undergoing DIS had shorter
durations of mechanical ventilation; consequently, it is not
possible to confirm that the sedation strategy may be the only
factor that contributes to the psychologic outcome. However,
the study does demonstrate that DIS did not lead to harmful
outcomes in this cohort.
The second concern, the possibility that DIS may precipitate
myocardial ischemia, is understandable given the established
recognition of ischemia with procedures such as intubation
and spontaneous breathing trials [37-41]. In response, we
evaluated the prevalence of myocardial ischemia in 74
mechanically ventilated patients with coronary risk factors,
comparing periods of sedative interruption with sedative
infusion [42]. Ischemia, defined by ST-segment changes
documented by continuous three-lead Holter monitor, was
interpreted by a cardiologist who was blinded to sedation
status. In the cohort of 74 patients, 24% exhibited ischemic
changes during the period of mechanical ventilation. Periods
of awakening from sedation (versus periods of sedative
infusion) were associated with significantly increased heart
rate, mean arterial pressure, rate-pressure product, respira-
tory rate, and catecholamine levels. Despite these physiologic
changes during sedative interruption, the fraction of ischemic
time did not differ between the time awake and the time
sedated. Therefore, within the limits of this study design,
myocardial ischemia was found to occur commonly during
mechanical ventilation in critically ill patients with coronary
artery disease risk factors, but DIS was not associated with a
heightened risk for ischemia.
Finally, concern for the interplay between sedative interrup-
tion and withdrawal syndromes is understandable. Alcohol
and other drug use disorders (AOD) affect 9.4% of the
American population [43], and the prevalence of these dis-
orders in ICUs ranges from 9% to 39% [44-48]. Studies
have demonstrated that selected patients with AOD have a
greater likelihood of being admitted to an ICU, increased risks
for requiring mechanical ventilation and developing sepsis,
septic shock, and acute lung injury, and increased hospital
mortality [47,49-52]. In a single center, retrospective review
of 70 mechanically ventilated patients, De Wit and coworkers
[48] documented AOD in 39% of patients. This cohort
experienced a 2.5-fold increased requirement for sedatives
and a fivefold higher dose of opioids compared with patients
without these disorders, but similar levels of sedation and
frequency of agitation were documented. Balancing of this
need for high doses of sedative and analgesic drugs in
mechanically ventilated patients with AOD against a desire to
minimize accumulation sets the stage for evolution of
dangerous withdrawal syndromes. Further investigation into
the safety of DIS in this population is needed.
Continuous versus intermittent sedative
administration
Given concern that continuous sedative infusions carry such
heightened risk for excessive sedation, guidelines have
postulated that intermittent bolus techniques utilizing
benzodiazepines might be an equivalent (or superior)
sedation strategy, even with daily interruption of sedative
infusions [53]. The comparison of these two strategies was
studied in two academic centers’ MICUs in an open label trial
of 132 patients requiring more than 48 hours of mechanical
ventilation and moderate to high levels of sedation [54].
Patients were randomly assigned to receive lorazepam by
intermittent bolus administration or continuous infusions of
propofol. In both groups, patients had sedation titrated to
achieve a target Ramsay Sedation Scale score of 2 (patient
cooperative, oriented, and tranquil) to 3 (patient responds to
commands only) [25], assessed every 2 hours. In the inter-
mittent group lorazepam was administered with usual dose
ranges of 2 to 4 mg every 4 hours; a peak dose of 8 mg was
considered acceptable. The continuous infusion group had
Critical Care    Vol 12 Suppl 3 Schweickert and Kress
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Figure 4
Duration of mechanical ventilation: DIS versus control. Shown is a
Kaplan-Meier analysis of the duration of mechanical ventilation,
according to study group: an intervention group, in which sedative
infusions were interrupted on a daily basis (DIS) until the patients were
awake; and a control group, in which the infusions were interrupted
only at the discretion of the clinicians in the intensive care unit. After
adjustment for baseline variables (age, sex, weight, Acute Physiology
and Chronic Health Evaluation II score, and type of respiratory failure),
mechanical ventilation was discontinued earlier in the intervention
group than in the control group (relative risk for extubation = 1.9, 95%
confidence interval = 1.3 to 2.7; P < 0.001). Reprinted with
permission from Kress JP, Pohlman AS, O’Connor MF, Hall JB: Daily
interruption of sedative infusions in critically ill patients undergoing
mechanical ventilation. N Engl J Med 2000, 342(20):1471-1477.
Copyright © 2000 Massachusetts Medical Society. All rights reserved.
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(n = 68)propofol titrated to peak dose of 4.8 mg/kg per hour (80 μg/kg
per minute). Both groups were administered concomitant
analgesia (utilizing morphine with allowance for continuous
drips if ventilator asynchrony was present) and daily interrup-
tion of sedation and analgesics. Patients were deemed
treatment failures if adequate sedation was not achieved by
8 mg lorazepam every 4 hours or a maximum dosage of
4.8 mg/kg per hour propofol, or - in the case of propofol -
development of hypertriglyceridemia, bradycardia, or hypo-
tension not attributable to another cause.
Although both groups had parallel distributions of time spent
in different levels of sedation, the primary outcome, namely
median ventilator days, was significantly lower in the daily
interruption propofol group than in the intermittent bolus
lorazepam group (5.8 days versus 8.4 days; P = 0.04;
Table 1). The difference was greatest for hospital survivors
(4.4 days versus 9.0 days; P = 0.006). Treatment failures
were low in both groups (4% and 8%). Of note, rates of self-
extubation were low in both groups (<5%), further suppor-
ting the safety of daily interruption of sedation.
The mechanism of benefit with daily interruption of continu-
ous propofol infusions cannot be delineated from the
available data. Possible explanations include persistent
sedative effect of benzodiazepines impairing spontaneous
breathing trial performance or increasing rates of delirium.
Alternatively, patients in the propofol arm did receive higher
morphine doses, which might have helped to improve the
frequency to tidal volume ratio observed during the
spontaneous breathing trials. Regardless, the randomized
study design, coupled with its multicenter implementation,
further strengthen the support for DIS, particularly with
protocols employing propofol. However, DIS has not been
tested utilizing ultra-short-acting agents such as remifentanil,
for which downward titration may be more appropriate until
data are available.
Implementing a sedation protocol
Despite the success of sedation protocols outlined above,
there is still surprisingly low implementation of sedation
scoring systems and sedation protocols in general practice.
Recent surveys of sedation practice patterns in Canada [55],
the USA [56], and Denmark [57] documented that formalized
sedation scoring systems/assessment tools are present in
≤50% of critical care units, with sedation protocols being
utilized in ≤33%.
Some of the reluctance to adopt sedation protocols may
stem from the absence of large-scale, multicenter, rando-
mized trials in the field, and from institutional and individual
bias regarding sedation scales and agents employed.
However, we believe that existing data support certain
conclusions. Successful sedation protocol implementation
requires three factors: frequent assessment of sedation and
analgesia using a reproducible scale; combination therapy
coupling sedatives and opioids with dosing adjustments
guided by the scale; and, most importantly, careful communi-
cation between team members, with particular recognition
that the bedside nurse must be empowered to pair
assessments with drug manipulation (Figure 5).
Critical care unit leadership must choose among an expansive
choice of sedation scales employed for patient assessment.
Sedation scales (discussed in detail in another review
included in this supplement [58]) differ in complexity, with
variable attention given to pain, agitation, and ventilator
synchrony. However, it remains to be demonstrated that use of
one scale as opposed to any other improves quality of care or
patient outcomes. We support the idea that ‘it may be more
important that the level of sedation is measured regularly and
reproducibly rather than the way it is measured’ [59].
To date, no single drug has successfully achieved all of the
indications for sedation and analgesia in the ICU. Accor-
dingly, we advocate a combination strategy. Previous recom-
mendations have always necessitated the need for analgesic
therapy to ensure that attention is given to pain, and all of the
Available online http://ccforum.com/content/12/S3/S6
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Table 1
Outcomes between patients randomized to intermittent bolus
lorazepam versus propofol with daily interruption 
Lorazepam Propofol  P
Ventilator days
All patients 8.4 (4.6, 14.7) 5.8 (3.5, 10.3) 0.04
Survivors 9.0 (5.3, 16.8) 4.4 (3.0, 8.7) 0.006
Nonsurvivors 7.5 (4.0, 11.4) 7.2 (4.2, 13.2) 0.66
28-day ventilator-free survival (days)
All patients 10.2 (0, 20) 18.5 (0, 24) 0.06
ICU length of stay (days)
All patients 10.4 (6.7, 16.8) 8.3 (5.2, 15.2) 0.20
Survivors 12.7 (7.8, 19.1) 8.6 (5.0, 14.7) 0.05
Nonsurvivors 9.5 (5.3, 12.0) 9.3 (6.0, 18.1) 0.68
Hospital length of stay (days)
All patients 20 (12, 30) 18 (12, 29) 0.55
Survivors 22.5 (14, 33) 19 (10, 32) 0.16
Hospital mortality (n [%]) 24 (38) 25 (37) 0.82
The total numbers of patients were 64 for the lorazepam group and 68
for the propofol group. Respectively, 40 and 43 patients survived
(‘survivors’), and 24 and 25 patients did not survive (‘nonsurvivors’).
Unless otherwise stated, values are expressed as median (25th, 75th
percentiles). ICU, intensive care unit. Adapted with permission from
Carson SS, Kress JP, Rodgers JE, Vinayak A, Campbell-Bright S, Levitt
J, Bourdet S, Ivanova A, Henderson AG, Pohlman A, et al.: A
randomized trial of intermittent lorazepam versus propofol with daily
interruption in mechanically ventilated patients. Crit Care Med 2006,
34(5):1326-1332.published, successful sedation protocols incorporate both
sedative and analgesic agents. Additionally, new evidence
reinforces the perception that combining sedatives and
analgesics may confer secondary benefits in achieving
optimal sedation. Richman and coworkers [60] conducted a
randomized trial of 30 patients with respiratory failure with an
expected duration of mechanical ventilation in excess of 48
hours who were receiving a sedative regimen that did not
include opiate pain control. Patients were randomly assigned
to continuous intravenous sedation with midazolam alone or
midazolam plus fentanyl (‘co-sedation’) during mechanical
ventilation, and were evaluated serially using a targeted
sedation scale. Compared with the midazolam-only group, the
co-sedation group had fewer hours per day with an ‘off-
target’ Ramsay Sedation Scale score and fewer episodes per
day of patient-ventilator asynchrony. Co-sedation was also
associated with nonsignificant trends toward a shorter time to
achieve sedation, a need for fewer dose titrations per day,
and a lower total sedative drug cost, without significant
difference between groups in the rate of adverse events.
Two additional comments are worth making. Deep analgesia
and sedation with resultant respiratory depression can
commonly quell patient-ventilator asynchrony, but optimal
management must include manipulation of the ventilator
(within the limits of the disease and proven ventilation
strategies) to achieve synchrony without relying upon
increased drug. This is most commonly achieved by selecting
modes that permit more spontaneous than controlled
ventilation [61]. Even in the setting of acute lung injury with
strict adherence to a low tidal volume ventilation protocol,
ventilator manipulation (changes in set respiratory rate,
inspiratory flow, and flow profile, with/without volume changes)
are feasible and should be entertained before acceleration of
drug [62]. Second, although this review highlights the
success of uniform practice protocols, consideration to
individual patient characteristics should be applied in the
selection of drugs to be utilized. Attention to organ system
dysfunction may demote certain drugs based on their
metabolism (for example, midazolam and morphine metabo-
lites accumulate in patients with renal insufficiency), and a
patient history of substance abuse may heighten the appeal
of other drugs (benzodiazepines). All successful protocols
incorporate limitations in generalizability, and the clinician
must recognize when deviation is indicated.
Finally, and most importantly, all of the sedation protocols that
have exhibited success have transferred the responsibility for
drug manipulation decisions to the bedside nurse. Although a
uniform goal should be set through physician and nurse
communication at the start of the day (at a minimum), the
variable response to drug administration and withdrawal
mandates an attendant clinician with the ability to respond in
rapid manner - the bedside nurse.
Conclusion
Sedation is a critical component in the management of the
mechanically ventilated patient. Given the poor predictability
of drug effect coupled with the hazards of inexact sedation
administration, we advocate the implementation of structured
assessment tools for pain and depth of sedation, coupled
with strategies to guide drug administration and withdrawal.
Although de-escalation strategies may differ, protocols that
guide the clinician to administer the least necessary sedation
Critical Care    Vol 12 Suppl 3 Schweickert and Kress
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Figure 5
Fundamental components of successful analgesia and sedation strategies. **Denotes components with evidence supporting their benefit.
**Sedation Scale Assessment
￿ Reproducible.Well understood by all team members
￿ Attends to level of conciousness, agitation and subtle
distress signals (grimacing, ventilator synchrony)
Distress?                   Awake?                 Pain?                      Goal
**Protocol-Guided,
Nurse-Initiated
Behaviors
**De-escalation of
Sedation and
Analgesia
￿ Daily interruption
￿ Protocol-guided withdrawal 1) Assess for Reversible Factors
2) Assess for Pain
3) Assess for Anxiety and Agitation
YES
NO YES                              NO
NO YES
￿ Verbal reassurance
￿ Patient Positioning
￿ Ventilator Manipulation
Pain-Free, Calm Patient
Able to undergo Complete
Cognitive and
Neuromuscular Evaluation
**Common Pairing of
Analgesia and sedation
Drug Administrationto achieve patient comfort while maintaining patient-examiner
interactivity yield demonstrable improvements in outcome.
Although the field needs more large-scale studies to guide
the protocol selection process, inattention to this aspect of
care may be costly.
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